RT Journal Article
T1 SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
A1 Cassinello, J
A1 Arranz, J A
A1 Piulats, J M
A1 Sanchez, A
A1 Perez-Valderrama, B
A1 Mellado, B
A1 Climent, M A
A1 Olmos, D
A1 Carles, J
A1 Lazaro, M
K1 Abiraterone
K1 Androgen deprivation treatment
K1 Cabazitaxel
K1 Castration-resistant prostate cancer
K1 Docetaxel
K1 Enzalutamide
K1 Hormone-sensitive advanced prostate cancer
K1 Radium 223
AB Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.
PB Springer
YR 2017
FD 2017-11-13
LK http://hdl.handle.net/10668/11795
UL http://hdl.handle.net/10668/11795
LA en
NO Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, et al. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):57-68
DS RISalud
RD Apr 18, 2025